Haizheng Pharmaceutical announced that the fourth extraordinary shareholders' meeting of the company in 2026 reviewed and passed a bill to authorize the introduction of Xuanjing Bionucleic Acid patented technology platform and RGN6669 products. A total of 631 shareholders and agents attended the meeting. The total number of voting shares held was 462,195,275 shares, accounting for 39.90% of the company's total voting shares, and 99.8479% of the votes approved by the bill. The procedures for convening, holding and voting at this shareholders' meeting were legal and compliant, and the resolution was legal and valid.

Haizheng Pharmaceutical announced that the fourth extraordinary shareholders' meeting of the company in 2026 reviewed and passed a bill to authorize the introduction of Xuanjing Bionucleic Acid patented technology platform and RGN6669 products. A total of 631 shareholders and agents attended the meeting. The total number of voting shares held was 462,195,275 shares, accounting for 39.90% of the company's total voting shares, and 99.8479% of the votes approved by the bill. The procedures for convening, holding and voting at this shareholders' meeting were legal and compliant, and the resolution was legal and valid.